Tagged with Opinion,

Singapore Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for orphan drug registration in four ASEAN countries and what more could be done to improve it.   Regulatory authorities such…

Global David H. Crean, Managing General Partner for Coast BioVentures, updates and highlights the latest trends in the cell and gene therapy market for deal activities and financings over the past two years since his original article on the topic was published on PharmaBoardroom in June 2019.   Cell and gene…

Global PharmaBoardroom’s network of thought leaders provided some of our best-read content in 2021 on topics ranging from China’s National Reimbursement Drug List to the vaccine row that erupted between AstraZeneca and the EU, the skills that pharma leaders need in the MEA region, the year’s most prominent trends, and how…

Global Shawview Consulting’s Brendan Shaw laments the descent into nationalism that COVID-19 – like past pandemics – has led to, and outlines his hopes that the World Health Assembly’s new accord on pandemic prevention, preparedness and response will lead to a more unified, global approach to future pandemics.   When Professor…

Global Marc Boutin, Novartis’ global head of patient engagement, outlines the company’s “bold vision” of patient engagement and the actions that need to be taken for CAR-T patients in the immediate, short- medium-, and long-term. This piece forms part of our special section, InFocus: Patient Engagaement in the Era of CAR-T.…

Global Walt Vernon is CEO of US-based healthcare facilities consulting firm, Mazzetti, and non-profit, Sextant. He is on the Board of the FGI and served on NFPA 99 ELS, NFPA 70 CMP15, and ASHRAE 189.3. He chairs the ASHRAE Infectious Aerosols Position Document Committee and represents the US in the International…

Africa Medicines for Africa’s Lenias Hwenda highlights the vast gaps in COVID-19 vaccine access globally, especially in Africa where just six percent of the population has been vaccinated. Hwenda argues that the time is now to boost the infrastructure for pharmaceutical manufacturing in Africa as a way out of this pandemic,…

Global The research evidence is unequivocal, public, planetary and economic health are inextricably linked and no continent, country or community is immune from the impacts of climate change. The race to net zero is also a race to a healthier, cleaner and more resilient future. Giles Dean, Sustainability Manager at Deloitte…

Global On the 100th anniversary of the development of insulin, regular PharmaBoardroom contributor Brendan Shaw* examines the shocking global disparities in access to the lifesaving drug, but does not point the finger of blame at the pharmaceutical industry. Instead, Shaw highlights the high barriers of entry that dissuade these companies from…

Mexico Writing in the November issue of DIA Global Forum, Lawrence Liberti, Mario Alanis, Pravin Chopra, and Silvia Bendiner examine how the COVID-19 pandemic facilitated greater inter-stakeholder collaboration across the healthcare ecosystems in Cuba and Mexico, and how the learnings from this period can be leveraged for better patient outcomes moving…

Australia In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already making to the global innovative pharmaceutical industry and why his country remains a particularly attractive clinical trials hub.   “We…

Europe In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global market access & pricing strategic planning at Merck Group, casts his eye across Europe to assess how sustainability criteria are…